Kodiak Sciences (NASDAQ:KOD - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.89) per share for the quarter.
Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.06. On average, analysts expect Kodiak Sciences to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Kodiak Sciences Stock Performance
NASDAQ:KOD opened at $4.03 on Wednesday. The stock has a market cap of $212.59 million, a price-to-earnings ratio of -1.10 and a beta of 2.42. Kodiak Sciences has a 1 year low of $1.92 and a 1 year high of $11.60. The business has a fifty day moving average of $3.29 and a 200-day moving average of $5.50.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a "neutral" rating and set a $3.00 target price on shares of Kodiak Sciences in a report on Monday, March 31st.
Check Out Our Latest Stock Analysis on Kodiak Sciences
About Kodiak Sciences
(
Get Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
